

# Disrupting the landscape: *the Plus One in RCC and NSCLC*

**SUNDAY 11<sup>TH</sup> SEPTEMBER 2022, 13:00–14:30 CEST,  
7.3. H – HONFLEUR AUDITORIUM, HALL 7, LEVEL 7.3  
PARIS PORTE DE VERSAILLES, PARIS, FRANCE**

*Then available on demand until Tuesday, 20 September 2022*

## **Welcome and introduction**

*Dr Laurence Albiges (Chairperson), France*

## **Triple, double and monotherapy: What is the sequence for best outcomes?**

*Dr Sumanta Pal, USA, with clinical cases from Dr Jens Bedke, Germany and Dr Guillermo de Velasco, Spain*

## **Expanding the armamentarium with TKI-IO combinations — what can be learnt from RCC for the future of NSCLC?**

*Dr Sumanta Pal, USA, and the full faculty*

## **Unmet needs in NSCLC: Choosing the “Plus One” in second-line**

*Dr Luis Paz-Ares, Spain*

## **Closing remarks and meeting close**

*Dr Laurence Albiges, France*